An Extensive Analysis of Computer-Aided Drug Design for Novel Psychotropic and Neurological Substances

Year : 2024 | Volume :01 | Issue : 02 | Page : 15-23
By

Satish kumar Yadav,

Mohd. Wasiullah,

Piyush Yadav,

Safiya Sajid,

Ms. Anjali Maurya,

  1. Associate professor, Department of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India
  2. Principal ,Department of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India
  3. Academic Head, Department Of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India
  4. Research Scholar, Department of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India
  5. Lecturer, Department of Pharmacy Prasad Institute of Technology, Jaunpur Uttar Pradesh India

Abstract

A comprehensive review of the use of computer-aided drug design (CADD) in the creation of innovative neurologic and neuropsychiatric medications is given in this article. It discusses the challenges in traditional drug discovery approaches and highlights the role of computational methods in accelerating the identification and optimization of drug candidates targeting psychiatric and neurological disorders. The method of finding new drugs has been completely transformed by Computer-Aided Drug Design (CADD), which combines medicinal chemistry concepts with computer tools. This review explores the applications of CADD in the development of psychotropic and neurological drugs. Beginning with an overview of psychotropic and neurological disorders, the article delves into the challenges faced in traditional drug discovery methods. It then elucidates the principles and methodologies of CADD, including molecular docking, pharmacophore modeling, and quantitative structure-activity relationship (QSAR) analysis. Subsequently, case studies highlight successful applications of CADD in the identification and optimization of lead compounds targeting various psychotropic and neurological targets. Finally, the review discusses future prospects and challenges in the field, emphasizing the potential of CADD to expedite the discovery of novel therapeutics for these debilitating disorders.

Keywords: ligand-based drug design; docking; QSAR; pharmacophore; Alzheimer’s disease; structure-based drug design; schizophrenia; neuropathic pain; neurological; deep learning; molecular dynamics; psychotropic; virtual screening; computer-aided drug design; artificial intelligence

[This article belongs to International Journal of Brain Sciences(ijbs)]

How to cite this article: Satish kumar Yadav, Mohd. Wasiullah, Piyush Yadav, Safiya Sajid, Ms. Anjali Maurya. An Extensive Analysis of Computer-Aided Drug Design for Novel Psychotropic and Neurological Substances. International Journal of Brain Sciences. 2024; 01(02):15-23.
How to cite this URL: Satish kumar Yadav, Mohd. Wasiullah, Piyush Yadav, Safiya Sajid, Ms. Anjali Maurya. An Extensive Analysis of Computer-Aided Drug Design for Novel Psychotropic and Neurological Substances. International Journal of Brain Sciences. 2024; 01(02):15-23. Available from: https://journals.stmjournals.com/ijbs/article=2024/view=155690

References

  1. Marioni, R. E. et al. GWAS on family history of Alzheimer’s disease. Transl. Psychiatry 8, 8–14 (2018).
  2. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
  3. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
  4. de Rojas, I. et al. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat. Commun. 12, 3417 (2021).
  5. Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes. Nat. Genet. (2021)
  6. Bellenguez, C. et al. New insights on the genetic etiology of Alzheimer’s and related dementia. medRxiv (2020).
  7. Wightman, D. P. et al. Largest GWAS (N=1,126,563) of Alzheimer ’s Disease Implicates Microglia and Immune Cells. bioRxiv 1–24 (2020).
  8. Patel, T. et al. Whole-exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 44, 506–521 (2018).
  9. Raghavan, N. S. et al. Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 1–11 (2018).
  10. Zerroug, A.; Belaidi, S.; BenBrahim, I.; Sinha, L.; Chtita, S. Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs. J. King Saud Univ. Sci. 2019, 31, 595–601.
  11. Vieira, T.; Magalhaes, R.; Sousa, S. Tailoring specialized scoring functions for more efficient virtual screening. Frontiers 2019, 2,1–4.
  12. Ray, R. Understanding the Structural Importance of the Non-Binding and Bindin Parts of Bedaquiline and Its Analogues with ATP Synthase Subunit. In Proceedings of the International Conference on Drug Discovery (ICDD) 2020, Hyderabad, India, 19 February 2020.
  13. Kotzabasaki, M.I.; Sotiropoulos, I.; Sarimveis, H. QSAR modeling of the toxicity classification of superparamagnetic iron oxide nanoparticles (SPIONs) in stem-cell monitoring applications: An integrated study from data curation to model development. RSC Adv. 2020, 10, 5385–5391
  14. Gbeddy, G.; Egodawatta, P.; Goonetilleke, A.; Ayoko, G.; Chen, L. Application of quantitative structure-activity relationship(QSAR) model in comprehensive human health risk assessment of PAHs, and alkyl-, nitro-, carbonyl-, and hydroxyl-PAHs laden in urban road dust. J. Hazard. Mater. 2020, 383, 121154.
  15. Du, M.; Qiu, Y.; Li, Q.; Li, Y. Efficacy coefficient method assisted quadruple-activities 3D-QSAR pharmacophore model for application in environmentally friendly PAE molecular modification. Environ. Sci. Pollut. Res. Int. 2020, 27, 24103–24114.Int. J. Mol. Sci. 2021, 22, 4688 16 of 22
  16. Fan, F.; Warshaviak, D.T.; Hamadeh, H.K.; Dunn, R.T. The integration Of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs. PLoS ONE 2019, 14, e0204378.
  17. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019, 15, 565–581
  18. Espinoza-Moraga, M.; Caballero, J.; Gaube, F.; Winckler, T.; Santos, L.S. 1-Benzyl-1,2,3,4-tetrahydro-β-carboline as channel blocker of N-methyl-D-aspartate receptors. Chem. Biol. Drug Des. 2012, 79, 594–599.
  19. Mishra, C.B.; Kumari, S.; Manral, A.; Prakash, A.; Saini, V.; Lynn, A.M.; Tiwari, M. Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 125, 736–750.
  20. Schmiedel, J.M.; Lehner, B. Determining protein structures using deep mutagenesis. Nat. Genet. 2019, 51, 1177.
  21. Kumar, J.; Ranjan, T.; Kumar, R.R.; Ansar, M.; Rajani, K.; Kumar, M.; Kumar, V.; Kumar, A. In silico Characterization and Homology Modelling of Potato Leaf Roll Virus (PLRV) Coat Protein. Curr. J. Appl. Sci. Technol. 2019, 1–8.
  22. Morales-Navarro, S.; Prent-Peñaloza, L.; Rodríguez Núñez, Y.A.; Sánchez-Aros, L.; Forero-Doria, O.; González, W.; Campilllo,N.E.; Reyes-Parada, M.; Martínez, A.; Ramírez, D. Theoretical and Experimental Approaches AiMed. at Drug Design Targeting Neurodegenerative Diseases. Processes 2019, 7, 940.
  23. Wang, B.; Dai, P.; Ding, D.; Del Rosario, A.; Grant, R.A.; Pentelute, B.L.; Laub, M.T. Affinity-based capture and identification of protein effectors of the growth regulator ppGpp. Nat. Chem. Biol. 2019, 15, 141–150.
  24. Chan, H.S.; Li, Y.; Dahoun, T.; Vogel, H.; Yuan, S. New binding sites, new opportunities for GPCR drug discovery. Trends Biochem. Sci. 2019, 44, 312–330.
  25. Zhang, Y.; Qiao, S.; Ji, S.; Han, N.; Liu, D.; Zhou, J. Identification of DNA–protein binding sites by bootstrap multiple convolutional neural networks on sequence information. Eng. Appl. Artif. Intell. 2019, 79, 58–66.
  26. Ye, W.; Wang, W.; Jiang, C.; Yu, Q.; Chen, H. Molecular dynamics simulations of amyloid fibrils: An in silico approach. Acta Biochim. Biophys. Sin. 2013, 45, 503–508.
  27. Makarasen, A.; Kuno, M.; Patnin, S.; Reukngam, N.; Khlaychan, P.; Deeyohe, S.; Intachote, P.; Saimanee, B.; Sengsai, S.; Boonsri, P.Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Drug Res. 2019, 69, 671–682.
Regular Issue Subscription Review Article
Volume 01
Issue 02
Received May 10, 2024
Accepted May 14, 2024
Published July 9, 2024
Views: 73